TDMS Study 05080-01 Pathology Tables
NTP STATISTICAL ANALYSIS OF PRIMARY TUMORS REPORT: PEIRPT08
LAB: Battelle Northwest ALLYL GLYCIDYL ETHER DATE: 09/10/94
EXPERIMENT: 05080 TEST: 01 TIME: 19:04:10
TEST TYPE: CHRONIC CAGES FROM 0000 TO LAST CAGE PAGE: 1
CONT: N01ES38061 ROUTE: RESPIRATORY EXPOSURE WHOLE BODY NTP C#: 56666
PATHOLOGIST: R. RENNE CAS: 106-92-3
------------------------------------------------------------------------------------------------------------------------------------
REASONS FOR REMOVAL: ALL
REMOVAL DATE RANGE: ALL
TREATMENT GROUPS: INCLUDE ALL
NTP STATISTICAL ANALYSIS OF PRIMARY TUMORS REPORT: PEIRPT08
LAB: Battelle Northwest ALLYL GLYCIDYL ETHER DATE: 09/10/94
EXPERIMENT: 05080 TEST: 01 TIME: 19:04:10
TEST TYPE: CHRONIC CAGES FROM 0000 TO LAST CAGE
CONT: N01ES38061 ROUTE: RESPIRATORY EXPOSURE WHOLE BODY NTP C#: 56666
PATHOLOGIST: R. RENNE CAS: 106-92-3
RATS(OSBORNE MENDEL)
----------------------------
FOR ALL DOSES THE TUMOR RATES IN THE FOLLOWING TISSUES/ORGANS ARE BASED ON NUMBER OF TISSUES EXAMINED.
IN OTHER TISSUES/ORGANS, RATES ARE BASED ON NUMBER OF ANIMALS NECROPSIED.
----------------
Adrenal Gland
Bone Marrow
Brain
Clitoral Gland
Epididymis
Heart
Islets, Pancreatic
Kidney
Larynx
Liver
Lung
Nose
Ovary
Pancreas
Parathyroid Gland
Pituitary Gland
Preputial Gland
Prostate
Salivary Glands
Spleen
Testes
Thymus
Thyroid Gland
Urinary Bladder
NTP STATISTICAL ANALYSIS OF PRIMARY TUMORS REPORT: PEIRPT08
LAB: Battelle Northwest ALLYL GLYCIDYL ETHER DATE: 09/10/94
EXPERIMENT: 05080 TEST: 01 TIME: 19:04:10
TEST TYPE: CHRONIC CAGES FROM 0000 TO LAST CAGE
CONT: N01ES38061 ROUTE: RESPIRATORY EXPOSURE WHOLE BODY NTP C#: 56666
PATHOLOGIST: R. RENNE CAS: 106-92-3
SUMMARY OF STATISTICALLY SIGNIFICANT (P<=.05) RESULTS
IN THE ANALYSIS OF THE STUDY OF ALLYL GLYCIDYL ETHER
====================================================================================================
MALE RATS
-------------
ORGAN MORPHOLOGY
------- ------------
Adrenal Medulla Pheochromocytoma Malignant
Thyroid Gland: C-Cell Adenoma
Carcinoma or Adenoma
All Organs Benign Tumors
Malignant and Benign Tumors
====================================================================================================
FEMALE RATS
-------------
ORGAN MORPHOLOGY
------- ------------
Islets, Pancreatic Adenoma
Carcinoma or Adenoma
All Organs Malignant Tumors
====================================================================================================
DATE: 09/10/94 EXPERIMENT: 05080 TEST: 01 PAGE 1
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN RATS(OSBORNE MENDEL) -- ALLYL GLYCIDYL ETHER
TERMINAL SACRIFICE AT 106 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 5 PPM 10 PPM | CONTROL 5 PPM 10 PPM |
| | MALE MALE MALE | FEMALE FEMALE FEMALE |
|=================================================================================================================================|
| |
|Adrenal Cortex |
| Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 1/48 (2%) 1/48 (2%) 2/48 (4%) | 3/50 (6%) 6/49 (12%) 2/49 (4%) |
|ADJUSTED (b) | 6.7% 6.7% 10.8% | 10.3% 17.2% 6.5% |
|TERMINAL (d) | 0/12 (0%) 0/11 (0%) 0/8 (0%) | 2/24 (8%) 3/30 (10%) 1/25 (4%) |
|FIRST INCIDENCE (DAYS) | 731 689 570 | 521 579 624 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.239 P=0.687 P=0.353 | P=0.430N P=0.305 P=0.497N |
|INCIDENTAL TUMOR | P=0.329 P=0.732 P=0.469 | P=0.478N P=0.204 P=0.567N |
|LOGISTIC REGRESSION | P=0.328 P=0.724 P=0.456 | P=0.449N P=0.231 P=0.517N |
|COCHRAN-ARMITAGE | P=0.378 | P=0.435N |
|FISHER EXACT | P=0.753N P=0.500 | P=0.233 P=0.510N |
|=================================================================================================================================|
| |
|Adrenal Medulla |
| Pheochromocytoma Benign |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 11/47 (23%) 14/47 (30%) 14/47 (30%) | 6/49 (12%) 2/48 (4%) 6/47 (13%) |
|ADJUSTED (b) | 60.7% 62.1% 50.7% | 21.1% 6.7% 22.9% |
|TERMINAL (d) | 6/12 (50%) 4/11 (36%) 1/8 (13%) | 3/24 (13%) 2/30 (7%) 5/24 (21%) |
|FIRST INCIDENCE (DAYS) | 586 500 303 | 667 737 (T) 624 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.069 P=0.197 P=0.099 | P=0.564 P=0.090N P=0.612 |
|INCIDENTAL TUMOR | P=0.246 P=0.243 P=0.375 | P=0.525 P=0.195N P=0.575 |
|LOGISTIC REGRESSION | P=0.184 P=0.227 P=0.241 | P=0.512 P=0.126N P=0.557 |
|COCHRAN-ARMITAGE | P=0.282 | P=0.542 |
|FISHER EXACT | P=0.321 P=0.321 | P=0.141N P=0.590 |
|=================================================================================================================================|
DATE: 09/10/94 EXPERIMENT: 05080 TEST: 01 PAGE 2
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN RATS(OSBORNE MENDEL) -- ALLYL GLYCIDYL ETHER
TERMINAL SACRIFICE AT 106 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 5 PPM 10 PPM | CONTROL 5 PPM 10 PPM |
| | MALE MALE MALE | FEMALE FEMALE FEMALE |
|=================================================================================================================================|
| |
|Adrenal Medulla |
| Pheochromocytoma Malignant |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 7/47 (15%) 0/47 (0%) 4/47 (9%) | 0/49 (0%) 0/48 (0%) 0/47 (0%) |
|ADJUSTED (b) | 36.6% 0.0% 32.2% | 0.0% 0.0% 0.0% |
|TERMINAL (d) | 3/12 (25%) 0/11 (0%) 2/8 (25%) | 0/24 (0%) 0/30 (0%) 0/24 (0%) |
|FIRST INCIDENCE (DAYS) | 604 --- 593 | --- --- --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.355N P=0.019N* P=0.544N | (e) (e) (e) |
|INCIDENTAL TUMOR | P=0.245N P=0.013N* P=0.397N | (e) (e) (e) |
|LOGISTIC REGRESSION | P=0.264N P=0.012N* P=0.414N | (e) (e) (e) |
|COCHRAN-ARMITAGE | P=0.168N | (e) |
|FISHER EXACT | P=0.006N** P=0.261N | (e) (e) |
|=================================================================================================================================|
| |
|Adrenal Medulla |
| Pheochromocytoma: Benign, Complex, Malignant, NOS |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 17/47 (36%) 14/47 (30%) 18/47 (38%) | 6/49 (12%) 2/48 (4%) 6/47 (13%) |
|ADJUSTED (b) | 77.8% 62.1% 68.2% | 21.1% 6.7% 22.9% |
|TERMINAL (d) | 8/12 (67%) 4/11 (36%) 3/8 (38%) | 3/24 (13%) 2/30 (7%) 5/24 (21%) |
|FIRST INCIDENCE (DAYS) | 586 500 303 | 667 737 (T) 624 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.106 P=0.537N P=0.122 | P=0.564 P=0.090N P=0.612 |
|INCIDENTAL TUMOR | P=0.365 P=0.419N P=0.471 | P=0.525 P=0.195N P=0.575 |
|LOGISTIC REGRESSION | P=0.297 P=0.425N P=0.347 | P=0.512 P=0.126N P=0.557 |
|COCHRAN-ARMITAGE | P=0.457 | P=0.542 |
|FISHER EXACT | P=0.331N P=0.500 | P=0.141N P=0.590 |
|=================================================================================================================================|
DATE: 09/10/94 EXPERIMENT: 05080 TEST: 01 PAGE 3
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN RATS(OSBORNE MENDEL) -- ALLYL GLYCIDYL ETHER
TERMINAL SACRIFICE AT 106 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 5 PPM 10 PPM | CONTROL 5 PPM 10 PPM |
| | MALE MALE MALE | FEMALE FEMALE FEMALE |
|=================================================================================================================================|
| |
|Brain |
| Granular Cell Tumor Benign |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 1/50 (2%) 0/50 (0%) 0/50 (0%) | 2/49 (4%) 0/50 (0%) 0/50 (0%) |
|ADJUSTED (b) | 3.1% 0.0% 0.0% | 6.6% 0.0% 0.0% |
|TERMINAL (d) | 0/12 (0%) 0/11 (0%) 0/8 (0%) | 1/23 (4%) 0/30 (0%) 0/25 (0%) |
|FIRST INCIDENCE (DAYS) | 604 --- --- | 579 --- --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.301N P=0.513N P=0.549N | P=0.092N P=0.213N P=0.239N |
|INCIDENTAL TUMOR | P=0.220N P=0.500N P=0.419N | P=0.083N P=0.181N P=0.231N |
|LOGISTIC REGRESSION | P=0.264N P=0.496N P=0.497N | P=0.093N P=0.233N P=0.234N |
|COCHRAN-ARMITAGE | P=0.269N | P=0.093N |
|FISHER EXACT | P=0.500N P=0.500N | P=0.242N P=0.242N |
|=================================================================================================================================|
| |
|Islets, Pancreatic |
| Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 0/48 (0%) 2/48 (4%) 1/45 (2%) | 4/50 (8%) 0/48 (0%) 0/48 (0%) |
|ADJUSTED (b) | 0.0% 18.2% 12.5% | 15.2% 0.0% 0.0% |
|TERMINAL (d) | 0/12 (0%) 2/11 (18%) 1/8 (13%) | 3/24 (13%) 0/30 (0%) 0/25 (0%) |
|FIRST INCIDENCE (DAYS) | --- 737 (T) 737 (T) | 705 --- --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.252 P=0.216 P=0.419 | P=0.013N* P=0.044N* P=0.062N |
|INCIDENTAL TUMOR | P=0.252 P=0.216 P=0.419 | P=0.016N* P=0.062N P=0.065N |
|LOGISTIC REGRESSION | P=0.252 P=0.216 P=0.419 | P=0.015N* P=0.056N P=0.065N |
|COCHRAN-ARMITAGE | P=0.343 | P=0.016N* |
|FISHER EXACT | P=0.247 P=0.484 | P=0.064N P=0.064N |
|=================================================================================================================================|
DATE: 09/10/94 EXPERIMENT: 05080 TEST: 01 PAGE 4
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN RATS(OSBORNE MENDEL) -- ALLYL GLYCIDYL ETHER
TERMINAL SACRIFICE AT 106 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 5 PPM 10 PPM | CONTROL 5 PPM 10 PPM |
| | MALE MALE MALE | FEMALE FEMALE FEMALE |
|=================================================================================================================================|
| |
|Islets, Pancreatic |
| Carcinoma or Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 0/48 (0%) 2/48 (4%) 1/45 (2%) | 4/50 (8%) 1/48 (2%) 0/48 (0%) |
|ADJUSTED (b) | 0.0% 18.2% 12.5% | 15.2% 3.3% 0.0% |
|TERMINAL (d) | 0/12 (0%) 2/11 (18%) 1/8 (13%) | 3/24 (13%) 1/30 (3%) 0/25 (0%) |
|FIRST INCIDENCE (DAYS) | --- 737 (T) 737 (T) | 705 737 (T) --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.252 P=0.216 P=0.419 | P=0.021N* P=0.129N P=0.062N |
|INCIDENTAL TUMOR | P=0.252 P=0.216 P=0.419 | P=0.025N* P=0.166N P=0.065N |
|LOGISTIC REGRESSION | P=0.252 P=0.216 P=0.419 | P=0.025N* P=0.160N P=0.065N |
|COCHRAN-ARMITAGE | P=0.343 | P=0.028N* |
|FISHER EXACT | P=0.247 P=0.484 | P=0.194N P=0.064N |
|=================================================================================================================================|
| |
|Kidney: Renal Tubule |
| Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 2/50 (4%) 0/49 (0%) 0/48 (0%) | 0/50 (0%) 0/48 (0%) 0/49 (0%) |
|ADJUSTED (b) | 13.4% 0.0% 0.0% | 0.0% 0.0% 0.0% |
|TERMINAL (d) | 1/12 (8%) 0/11 (0%) 0/8 (0%) | 0/24 (0%) 0/30 (0%) 0/25 (0%) |
|FIRST INCIDENCE (DAYS) | 719 --- --- | --- --- --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.156N P=0.294N P=0.366N | (e) (e) (e) |
|INCIDENTAL TUMOR | P=0.136N P=0.265N P=0.333N | (e) (e) (e) |
|LOGISTIC REGRESSION | P=0.153N P=0.297N P=0.364N | (e) (e) (e) |
|COCHRAN-ARMITAGE | P=0.099N | (e) |
|FISHER EXACT | P=0.253N P=0.258N | (e) (e) |
|=================================================================================================================================|
DATE: 09/10/94 EXPERIMENT: 05080 TEST: 01 PAGE 5
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN RATS(OSBORNE MENDEL) -- ALLYL GLYCIDYL ETHER
TERMINAL SACRIFICE AT 106 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 5 PPM 10 PPM | CONTROL 5 PPM 10 PPM |
| | MALE MALE MALE | FEMALE FEMALE FEMALE |
|=================================================================================================================================|
| |
|Liver |
| Hepatocellular Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 0/49 (0%) 1/49 (2%) 0/47 (0%) | 3/50 (6%) 3/48 (6%) 1/49 (2%) |
|ADJUSTED (b) | 0.0% 9.1% 0.0% | 12.5% 10.0% 4.0% |
|TERMINAL (d) | 0/12 (0%) 1/11 (9%) 0/8 (0%) | 3/24 (13%) 3/30 (10%) 1/25 (4%) |
|FIRST INCIDENCE (DAYS) | --- 737 (T) --- | 737 (T) 737 (T) 737 (T) |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.680 P=0.483 (e) | P=0.214N P=0.557N P=0.288N |
|INCIDENTAL TUMOR | P=0.680 P=0.483 (e) | P=0.214N P=0.557N P=0.288N |
|LOGISTIC REGRESSION | P=0.680 P=0.483 (e) | P=0.214N P=0.557N P=0.288N |
|COCHRAN-ARMITAGE | P=0.726 | P=0.247N |
|FISHER EXACT | P=0.500 (e) | P=0.641 P=0.316N |
|=================================================================================================================================|
| |
|Liver |
| Hepatocellular Carcinoma or Hepatocellular Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 0/49 (0%) 2/49 (4%) 0/47 (0%) | 3/50 (6%) 3/48 (6%) 1/49 (2%) |
|ADJUSTED (b) | 0.0% 13.2% 0.0% | 12.5% 10.0% 4.0% |
|TERMINAL (d) | 0/12 (0%) 1/11 (9%) 0/8 (0%) | 3/24 (13%) 3/30 (10%) 1/25 (4%) |
|FIRST INCIDENCE (DAYS) | --- 659 --- | 737 (T) 737 (T) 737 (T) |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.581 P=0.216 (e) | P=0.214N P=0.557N P=0.288N |
|INCIDENTAL TUMOR | P=0.574 P=0.215 (e) | P=0.214N P=0.557N P=0.288N |
|LOGISTIC REGRESSION | P=0.591 P=0.206 (e) | P=0.214N P=0.557N P=0.288N |
|COCHRAN-ARMITAGE | P=0.660 | P=0.247N |
|FISHER EXACT | P=0.247 (e) | P=0.641 P=0.316N |
|=================================================================================================================================|
DATE: 09/10/94 EXPERIMENT: 05080 TEST: 01 PAGE 6
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN RATS(OSBORNE MENDEL) -- ALLYL GLYCIDYL ETHER
TERMINAL SACRIFICE AT 106 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 5 PPM 10 PPM | CONTROL 5 PPM 10 PPM |
| | MALE MALE MALE | FEMALE FEMALE FEMALE |
|=================================================================================================================================|
| |
|Liver |
| Hepatocellular Carcinoma, Hepatocellular Adenoma, or Hepatoblastoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 0/49 (0%) 2/49 (4%) 0/47 (0%) | 3/50 (6%) 3/48 (6%) 1/49 (2%) |
|ADJUSTED (b) | 0.0% 13.2% 0.0% | 12.5% 10.0% 4.0% |
|TERMINAL (d) | 0/12 (0%) 1/11 (9%) 0/8 (0%) | 3/24 (13%) 3/30 (10%) 1/25 (4%) |
|FIRST INCIDENCE (DAYS) | --- 659 --- | 737 (T) 737 (T) 737 (T) |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.581 P=0.216 (e) | P=0.214N P=0.557N P=0.288N |
|INCIDENTAL TUMOR | P=0.574 P=0.215 (e) | P=0.214N P=0.557N P=0.288N |
|LOGISTIC REGRESSION | P=0.591 P=0.206 (e) | P=0.214N P=0.557N P=0.288N |
|COCHRAN-ARMITAGE | P=0.660 | P=0.247N |
|FISHER EXACT | P=0.247 (e) | P=0.641 P=0.316N |
|=================================================================================================================================|
| |
|Mammary Gland |
| Carcinoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 0/50 (0%) 0/50 (0%) | 2/50 (4%) 6/50 (12%) 4/50 (8%) |
|ADJUSTED (b) | 0.0% 0.0% 0.0% | 5.4% 16.7% 12.1% |
|TERMINAL (d) | 0/12 (0%) 0/11 (0%) 0/8 (0%) | 0/24 (0%) 2/30 (7%) 2/25 (8%) |
|FIRST INCIDENCE (DAYS) | --- --- --- | 569 318 269 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | (e) (e) (e) | P=0.290 P=0.179 P=0.339 |
|INCIDENTAL TUMOR | (e) (e) (e) | P=0.359 P=0.066 P=0.409 |
|LOGISTIC REGRESSION | (e) (e) (e) | P=0.317 P=0.137 P=0.378 |
|COCHRAN-ARMITAGE | (e) | P=0.290 |
|FISHER EXACT | (e) (e) | P=0.134 P=0.339 |
|=================================================================================================================================|
DATE: 09/10/94 EXPERIMENT: 05080 TEST: 01 PAGE 7
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN RATS(OSBORNE MENDEL) -- ALLYL GLYCIDYL ETHER
TERMINAL SACRIFICE AT 106 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 5 PPM 10 PPM | CONTROL 5 PPM 10 PPM |
| | MALE MALE MALE | FEMALE FEMALE FEMALE |
|=================================================================================================================================|
| |
|Mammary Gland |
| Fibroadenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 0/50 (0%) 2/50 (4%) | 23/50 (46%) 19/50 (38%) 22/50 (44%) |
|ADJUSTED (b) | 0.0% 0.0% 6.8% | 60.0% 48.4% 59.8% |
|TERMINAL (d) | 0/12 (0%) 0/11 (0%) 0/8 (0%) | 10/24 (42%) 11/30 (37%) 11/25 (44%) |
|FIRST INCIDENCE (DAYS) | --- --- 520 | 474 471 332 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.085 (e) P=0.214 | P=0.469N P=0.175N P=0.501N |
|INCIDENTAL TUMOR | P=0.099 (e) P=0.249 | P=0.462 P=0.287N P=0.476 |
|LOGISTIC REGRESSION | P=0.104 (e) P=0.254 | P=0.510N P=0.277N P=0.556N |
|COCHRAN-ARMITAGE | P=0.095 | P=0.460N |
|FISHER EXACT | (e) P=0.247 | P=0.272N P=0.500N |
|=================================================================================================================================|
| |
|Mammary Gland |
| Fibroma, Fibroadenoma, Carcinoma, or Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 0/50 (0%) 2/50 (4%) | 25/50 (50%) 24/50 (48%) 26/50 (52%) |
|ADJUSTED (b) | 0.0% 0.0% 6.8% | 62.2% 56.4% 67.1% |
|TERMINAL (d) | 0/12 (0%) 0/11 (0%) 0/8 (0%) | 10/24 (42%) 12/30 (40%) 13/25 (52%) |
|FIRST INCIDENCE (DAYS) | --- --- 520 | 474 318 269 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.085 (e) P=0.214 | P=0.461 P=0.333N P=0.498 |
|INCIDENTAL TUMOR | P=0.099 (e) P=0.249 | P=0.344 P=0.554 P=0.355 |
|LOGISTIC REGRESSION | P=0.104 (e) P=0.254 | P=0.427 P=0.576 P=0.462 |
|COCHRAN-ARMITAGE | P=0.095 | P=0.460 |
|FISHER EXACT | (e) P=0.247 | P=0.500N P=0.500 |
|=================================================================================================================================|
DATE: 09/10/94 EXPERIMENT: 05080 TEST: 01 PAGE 8
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN RATS(OSBORNE MENDEL) -- ALLYL GLYCIDYL ETHER
TERMINAL SACRIFICE AT 106 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 5 PPM 10 PPM | CONTROL 5 PPM 10 PPM |
| | MALE MALE MALE | FEMALE FEMALE FEMALE |
|=================================================================================================================================|
| |
|Parathyroid Gland |
| Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 1/36 (3%) 0/30 (0%) 2/38 (5%) | 0/26 (0%) 0/32 (0%) 0/33 (0%) |
|ADJUSTED (b) | 3.3% 0.0% 5.1% | 0.0% 0.0% 0.0% |
|TERMINAL (d) | 0/10 (0%) 0/8 (0%) 0/6 (0%) | 0/8 (0%) 0/18 (0%) 0/21 (0%) |
|FIRST INCIDENCE (DAYS) | 609 --- 303 | --- --- --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.330 P=0.507N P=0.458 | (e) (e) (e) |
|INCIDENTAL TUMOR | P=0.593 P=0.521N P=0.726 | (e) (e) (e) |
|LOGISTIC REGRESSION | P=0.543 P=0.540N P=0.681 | (e) (e) (e) |
|COCHRAN-ARMITAGE | P=0.379 | (e) |
|FISHER EXACT | P=0.545N P=0.521 | (e) (e) |
|=================================================================================================================================|
| |
|Pituitary Gland: Pars Distalis or Unspecified Site |
| Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 11/47 (23%) 12/46 (26%) 13/44 (30%) | 26/50 (52%) 26/45 (58%) 20/48 (42%) |
|ADJUSTED (b) | 56.3% 55.9% 61.2% | 67.4% 71.6% 71.1% |
|TERMINAL (d) | 4/11 (36%) 3/10 (30%) 2/7 (29%) | 12/24 (50%) 18/28 (64%) 17/25 (68%) |
|FIRST INCIDENCE (DAYS) | 578 591 568 | 478 569 658 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.093 P=0.343 P=0.120 | P=0.137N P=0.380N P=0.165N |
|INCIDENTAL TUMOR | P=0.269 P=0.407 P=0.293 | P=0.157N P=0.321 P=0.187N |
|LOGISTIC REGRESSION | P=0.167 P=0.397 P=0.202 | P=0.185N P=0.376 P=0.212N |
|COCHRAN-ARMITAGE | P=0.293 | P=0.182N |
|FISHER EXACT | P=0.476 P=0.335 | P=0.360 P=0.206N |
|=================================================================================================================================|
DATE: 09/10/94 EXPERIMENT: 05080 TEST: 01 PAGE 9
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN RATS(OSBORNE MENDEL) -- ALLYL GLYCIDYL ETHER
TERMINAL SACRIFICE AT 106 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 5 PPM 10 PPM | CONTROL 5 PPM 10 PPM |
| | MALE MALE MALE | FEMALE FEMALE FEMALE |
|=================================================================================================================================|
| |
|Pituitary Gland: Pars Distalis or Unspecified Site |
| Carcinoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 2/47 (4%) 0/46 (0%) 0/44 (0%) | 1/50 (2%) 0/45 (0%) 1/48 (2%) |
|ADJUSTED (b) | 14.1% 0.0% 0.0% | 2.9% 0.0% 2.4% |
|TERMINAL (d) | 1/11 (9%) 0/10 (0%) 0/7 (0%) | 0/24 (0%) 0/28 (0%) 0/25 (0%) |
|FIRST INCIDENCE (DAYS) | 719 --- --- | 683 --- 570 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.158N P=0.295N P=0.372N | P=0.661 P=0.506N P=0.754 |
|INCIDENTAL TUMOR | P=0.137N P=0.259N P=0.342N | P=0.640 P=0.654N P=0.742 |
|LOGISTIC REGRESSION | P=0.160N P=0.299N P=0.382N | P=0.665 P=0.521N P=0.761 |
|COCHRAN-ARMITAGE | P=0.101N | P=0.658 |
|FISHER EXACT | P=0.253N P=0.264N | P=0.526N P=0.742 |
|=================================================================================================================================|
| |
|Pituitary Gland: Pars Distalis or Unspecified Site |
| Carcinoma or Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 13/47 (28%) 12/46 (26%) 13/44 (30%) | 27/50 (54%) 26/45 (58%) 21/48 (44%) |
|ADJUSTED (b) | 64.6% 55.9% 61.2% | 68.4% 71.6% 71.8% |
|TERMINAL (d) | 5/11 (45%) 3/10 (30%) 2/7 (29%) | 12/24 (50%) 18/28 (64%) 17/25 (68%) |
|FIRST INCIDENCE (DAYS) | 578 591 568 | 478 569 570 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.171 P=0.492 P=0.201 | P=0.144N P=0.320N P=0.175N |
|INCIDENTAL TUMOR | P=0.427 P=0.594 P=0.440 | P=0.160N P=0.371 P=0.194N |
|LOGISTIC REGRESSION | P=0.299 P=0.581 P=0.335 | P=0.192N P=0.456 P=0.222N |
|COCHRAN-ARMITAGE | P=0.469 | P=0.183N |
|FISHER EXACT | P=0.525N P=0.513 | P=0.435 P=0.208N |
|=================================================================================================================================|
DATE: 09/10/94 EXPERIMENT: 05080 TEST: 01 PAGE 10
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN RATS(OSBORNE MENDEL) -- ALLYL GLYCIDYL ETHER
TERMINAL SACRIFICE AT 106 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 5 PPM 10 PPM | CONTROL 5 PPM 10 PPM |
| | MALE MALE MALE | FEMALE FEMALE FEMALE |
|=================================================================================================================================|
| |
|Pituitary Gland: Pars Intermedia |
| Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 0/47 (0%) 2/46 (4%) 2/44 (5%) | 0/50 (0%) 0/45 (0%) 0/48 (0%) |
|ADJUSTED (b) | 0.0% 20.0% 16.3% | 0.0% 0.0% 0.0% |
|TERMINAL (d) | 0/11 (0%) 2/10 (20%) 1/7 (14%) | 0/24 (0%) 0/28 (0%) 0/25 (0%) |
|FIRST INCIDENCE (DAYS) | --- 737 (T) 520 | --- --- --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.108 P=0.213 P=0.195 | (e) (e) (e) |
|INCIDENTAL TUMOR | P=0.079 P=0.213 P=0.126 | (e) (e) (e) |
|LOGISTIC REGRESSION | P=0.118 P=0.213 P=0.217 | (e) (e) (e) |
|COCHRAN-ARMITAGE | P=0.161 | (e) |
|FISHER EXACT | P=0.242 P=0.231 | (e) (e) |
|=================================================================================================================================|
| |
|Skin |
| Fibroma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 2/50 (4%) 0/50 (0%) 1/50 (2%) | 0/50 (0%) 1/50 (2%) 0/50 (0%) |
|ADJUSTED (b) | 9.0% 0.0% 5.6% | 0.0% 3.3% 0.0% |
|TERMINAL (d) | 0/12 (0%) 0/11 (0%) 0/8 (0%) | 0/24 (0%) 1/30 (3%) 0/25 (0%) |
|FIRST INCIDENCE (DAYS) | 327 --- 652 | --- 737 (T) --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.457N P=0.269N P=0.621N | P=0.732N P=0.545 (e) |
|INCIDENTAL TUMOR | P=0.272N P=0.255N P=0.432N | P=0.732N P=0.545 (e) |
|LOGISTIC REGRESSION | P=0.326N P=0.217N P=0.463N | P=0.732N P=0.545 (e) |
|COCHRAN-ARMITAGE | P=0.360N | P=0.731 |
|FISHER EXACT | P=0.247N P=0.500N | P=0.500 (e) |
|=================================================================================================================================|
DATE: 09/10/94 EXPERIMENT: 05080 TEST: 01 PAGE 11
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN RATS(OSBORNE MENDEL) -- ALLYL GLYCIDYL ETHER
TERMINAL SACRIFICE AT 106 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 5 PPM 10 PPM | CONTROL 5 PPM 10 PPM |
| | MALE MALE MALE | FEMALE FEMALE FEMALE |
|=================================================================================================================================|
| |
|Skin |
| Sarcoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 2/50 (4%) 0/50 (0%) | 0/50 (0%) 2/50 (4%) 0/50 (0%) |
|ADJUSTED (b) | 0.0% 4.5% 0.0% | 0.0% 5.5% 0.0% |
|TERMINAL (d) | 0/12 (0%) 0/11 (0%) 0/8 (0%) | 0/24 (0%) 1/30 (3%) 0/25 (0%) |
|FIRST INCIDENCE (DAYS) | --- 444 --- | --- 547 --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.666 P=0.242 (e) | P=0.669N P=0.267 (e) |
|INCIDENTAL TUMOR | P=0.629 P=0.307 (e) | P=0.670N P=0.297 (e) |
|LOGISTIC REGRESSION | P=0.575N P=0.260 (e) | P=0.665N P=0.240 (e) |
|COCHRAN-ARMITAGE | P=0.669 | P=0.669 |
|FISHER EXACT | P=0.247 (e) | P=0.247 (e) |
|=================================================================================================================================|
| |
|Stomach, Forestomach |
| Squamous Cell Carcinoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 1/50 (2%) 2/50 (4%) 1/50 (2%) | 0/50 (0%) 1/50 (2%) 0/50 (0%) |
|ADJUSTED (b) | 8.3% 5.1% 12.5% | 0.0% 2.1% 0.0% |
|TERMINAL (d) | 1/12 (8%) 0/11 (0%) 1/8 (13%) | 0/24 (0%) 0/30 (0%) 0/25 (0%) |
|FIRST INCIDENCE (DAYS) | 737 (T) 526 737 (T) | --- 396 --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.556 P=0.481 P=0.672 | P=0.716 P=0.496 (e) |
|INCIDENTAL TUMOR | P=0.577 P=0.526 P=0.672 | P=0.601 P=0.398 (e) |
|LOGISTIC REGRESSION | P=0.598 P=0.506 P=0.672 | P=0.645N P=0.541 (e) |
|COCHRAN-ARMITAGE | P=0.622N | P=0.731 |
|FISHER EXACT | P=0.500 P=0.753N | P=0.500 (e) |
|=================================================================================================================================|
DATE: 09/10/94 EXPERIMENT: 05080 TEST: 01 PAGE 12
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN RATS(OSBORNE MENDEL) -- ALLYL GLYCIDYL ETHER
TERMINAL SACRIFICE AT 106 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 5 PPM 10 PPM | CONTROL 5 PPM 10 PPM |
| | MALE MALE MALE | FEMALE FEMALE FEMALE |
|=================================================================================================================================|
| |
|Stomach, Forestomach |
| Squamous Cell Carcinoma or Papilloma Squamous |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 2/50 (4%) 2/50 (4%) 1/50 (2%) | 0/50 (0%) 1/50 (2%) 1/50 (2%) |
|ADJUSTED (b) | 12.5% 5.1% 12.5% | 0.0% 2.1% 2.9% |
|TERMINAL (d) | 1/12 (8%) 0/11 (0%) 1/8 (13%) | 0/24 (0%) 0/30 (0%) 0/25 (0%) |
|FIRST INCIDENCE (DAYS) | 684 526 737 (T) | --- 396 652 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.501N P=0.643 P=0.672N | P=0.318 P=0.496 P=0.494 |
|INCIDENTAL TUMOR | P=0.461N P=0.685N P=0.641N | P=0.232 P=0.398 P=0.467 |
|LOGISTIC REGRESSION | P=0.428N P=0.694 P=0.674N | P=0.390 P=0.541 P=0.500 |
|COCHRAN-ARMITAGE | P=0.390N | P=0.331 |
|FISHER EXACT | P=0.691N P=0.500N | P=0.500 P=0.500 |
|=================================================================================================================================|
| |
|Thyroid Gland: C-Cell |
| Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 8/43 (19%) 10/46 (22%) 12/46 (26%) | 11/49 (22%) 19/47 (40%) 12/47 (26%) |
|ADJUSTED (b) | 40.6% 52.8% 61.4% | 36.7% 55.2% 40.1% |
|TERMINAL (d) | 3/12 (25%) 4/11 (36%) 3/8 (38%) | 6/24 (25%) 15/30 (50%) 8/25 (32%) |
|FIRST INCIDENCE (DAYS) | 586 531 593 | 690 547 624 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.036 * P=0.263 P=0.049 * | P=0.478 P=0.175 P=0.516 |
|INCIDENTAL TUMOR | P=0.140 P=0.371 P=0.225 | P=0.411 P=0.051 P=0.454 |
|LOGISTIC REGRESSION | P=0.092 P=0.346 P=0.126 | P=0.379 P=0.053 P=0.440 |
|COCHRAN-ARMITAGE | P=0.235 | P=0.404 |
|FISHER EXACT | P=0.459 P=0.278 | P=0.046 * P=0.454 |
|=================================================================================================================================|
DATE: 09/10/94 EXPERIMENT: 05080 TEST: 01 PAGE 13
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN RATS(OSBORNE MENDEL) -- ALLYL GLYCIDYL ETHER
TERMINAL SACRIFICE AT 106 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 5 PPM 10 PPM | CONTROL 5 PPM 10 PPM |
| | MALE MALE MALE | FEMALE FEMALE FEMALE |
|=================================================================================================================================|
| |
|Thyroid Gland: C-Cell |
| Carcinoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 5/43 (12%) 1/46 (2%) 3/46 (7%) | 4/49 (8%) 2/47 (4%) 4/47 (9%) |
|ADJUSTED (b) | 32.5% 9.1% 28.7% | 16.7% 5.9% 13.2% |
|TERMINAL (d) | 2/12 (17%) 1/11 (9%) 1/8 (13%) | 4/24 (17%) 1/30 (3%) 1/25 (4%) |
|FIRST INCIDENCE (DAYS) | 719 737 (T) 681 | 737 (T) 642 624 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.495N P=0.150N P=0.644 | P=0.570N P=0.253N P=0.628N |
|INCIDENTAL TUMOR | P=0.449N P=0.119N P=0.606N | P=0.553 P=0.244N P=0.621 |
|LOGISTIC REGRESSION | P=0.525N P=0.166N P=0.646 | P=0.546 P=0.332N P=0.615 |
|COCHRAN-ARMITAGE | P=0.235N | P=0.557 |
|FISHER EXACT | P=0.087N P=0.319N | P=0.359N P=0.619 |
|=================================================================================================================================|
| |
|Thyroid Gland: C-Cell |
| Carcinoma or Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 11/43 (26%) 11/46 (24%) 15/46 (33%) | 14/49 (29%) 21/47 (45%) 14/47 (30%) |
|ADJUSTED (b) | 54.7% 59.5% 74.9% | 47.2% 59.3% 45.6% |
|TERMINAL (d) | 4/12 (33%) 5/11 (45%) 4/8 (50%) | 9/24 (38%) 16/30 (53%) 9/25 (36%) |
|FIRST INCIDENCE (DAYS) | 586 531 593 | 690 547 624 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.028 * P=0.424 P=0.036 * | P=0.517N P=0.274 P=0.563N |
|INCIDENTAL TUMOR | P=0.102 P=0.563 P=0.151 | P=0.498 P=0.107 P=0.549 |
|LOGISTIC REGRESSION | P=0.061 P=0.515 P=0.079 | P=0.460 P=0.087 P=0.531 |
|COCHRAN-ARMITAGE | P=0.262 | P=0.484 |
|FISHER EXACT | P=0.525N P=0.311 | P=0.077 P=0.537 |
|=================================================================================================================================|
DATE: 09/10/94 EXPERIMENT: 05080 TEST: 01 PAGE 14
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN RATS(OSBORNE MENDEL) -- ALLYL GLYCIDYL ETHER
TERMINAL SACRIFICE AT 106 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 5 PPM 10 PPM | CONTROL 5 PPM 10 PPM |
| | MALE MALE MALE | FEMALE FEMALE FEMALE |
|=================================================================================================================================|
| |
|Uterus |
| Carcinoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | # # # |
|----------- | | |
|OVERALL (a) | | 2/50 (4%) 0/50 (0%) 3/50 (6%) |
|ADJUSTED (b) | | 7.3% 0.0% 9.1% |
|TERMINAL (d) | | 0/24 (0%) 0/30 (0%) 1/25 (4%) |
|FIRST INCIDENCE (DAYS) | | 723 --- 578 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | | P=0.385 P=0.206N P=0.493 |
|INCIDENTAL TUMOR | | P=0.356 P=0.418N P=0.458 |
|LOGISTIC REGRESSION | | P=0.376 P=0.226N P=0.482 |
|COCHRAN-ARMITAGE | | P=0.390 |
|FISHER EXACT | | P=0.247N P=0.500 |
|=================================================================================================================================|
| |
|Uterus |
| Polyp Stromal |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | # # # |
|----------- | | |
|OVERALL (a) | | 10/50 (20%) 11/50 (22%) 9/50 (18%) |
|ADJUSTED (b) | | 34.7% 31.0% 33.8% |
|TERMINAL (d) | | 6/24 (25%) 7/30 (23%) 8/25 (32%) |
|FIRST INCIDENCE (DAYS) | | 690 318 624 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | | P=0.433N P=0.519N P=0.478N |
|INCIDENTAL TUMOR | | P=0.390N P=0.462 P=0.505N |
|LOGISTIC REGRESSION | | P=0.502N P=0.494 P=0.537N |
|COCHRAN-ARMITAGE | | P=0.450N |
|FISHER EXACT | | P=0.500 P=0.500N |
|=================================================================================================================================|
DATE: 09/10/94 EXPERIMENT: 05080 TEST: 01 PAGE 15
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN RATS(OSBORNE MENDEL) -- ALLYL GLYCIDYL ETHER
TERMINAL SACRIFICE AT 106 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 5 PPM 10 PPM | CONTROL 5 PPM 10 PPM |
| | MALE MALE MALE | FEMALE FEMALE FEMALE |
|=================================================================================================================================|
| |
|Uterus |
| Sarcoma Stromal |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | # # # |
|----------- | | |
|OVERALL (a) | | 1/50 (2%) 2/50 (4%) 1/50 (2%) |
|ADJUSTED (b) | | 2.4% 5.4% 3.6% |
|TERMINAL (d) | | 0/24 (0%) 1/30 (3%) 0/25 (0%) |
|FIRST INCIDENCE (DAYS) | | 579 408 729 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | | P=0.616 P=0.518 P=0.760 |
|INCIDENTAL TUMOR | | P=0.536 P=0.501 P=0.742 |
|LOGISTIC REGRESSION | | P=0.598N P=0.519 P=0.763 |
|COCHRAN-ARMITAGE | | P=0.622N |
|FISHER EXACT | | P=0.500 P=0.753N |
|=================================================================================================================================|
| |
|Uterus |
| Sarcoma Stromal or Polyp Stromal |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | # # # |
|----------- | | |
|OVERALL (a) | | 11/50 (22%) 13/50 (26%) 10/50 (20%) |
|ADJUSTED (b) | | 36.2% 35.4% 36.2% |
|TERMINAL (d) | | 6/24 (25%) 8/30 (27%) 8/25 (32%) |
|FIRST INCIDENCE (DAYS) | | 579 318 624 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | | P=0.439N P=0.577 P=0.479N |
|INCIDENTAL TUMOR | | P=0.429N P=0.372 P=0.513N |
|LOGISTIC REGRESSION | | P=0.502N P=0.403 P=0.549N |
|COCHRAN-ARMITAGE | | P=0.452N |
|FISHER EXACT | | P=0.408 P=0.500N |
|=================================================================================================================================|
DATE: 09/10/94 EXPERIMENT: 05080 TEST: 01 PAGE 16
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN RATS(OSBORNE MENDEL) -- ALLYL GLYCIDYL ETHER
TERMINAL SACRIFICE AT 106 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 5 PPM 10 PPM | CONTROL 5 PPM 10 PPM |
| | MALE MALE MALE | FEMALE FEMALE FEMALE |
|=================================================================================================================================|
| |
|All Organs |
| Malignant Lymphoma And Histiocytic Sarcoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 3/50 (6%) 3/50 (6%) 4/50 (8%) | 1/50 (2%) 2/50 (4%) 2/50 (4%) |
|ADJUSTED (b) | 12.8% 16.5% 13.7% | 3.0% 5.9% 4.8% |
|TERMINAL (d) | 1/12 (8%) 0/11 (0%) 0/8 (0%) | 0/24 (0%) 0/30 (0%) 0/25 (0%) |
|FIRST INCIDENCE (DAYS) | 449 635 580 | 690 674 281 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.282 P=0.591 P=0.408 | P=0.379 P=0.512 P=0.494 |
|INCIDENTAL TUMOR | P=0.482 P=0.656 P=0.604 | P=0.414 P=0.233 P=0.581 |
|LOGISTIC REGRESSION | P=0.409 P=0.659 P=0.521 | P=0.425 P=0.499 P=0.576 |
|COCHRAN-ARMITAGE | P=0.421 | P=0.390 |
|FISHER EXACT | P=0.661N P=0.500 | P=0.500 P=0.500 |
|=================================================================================================================================|
| |
|All Organs |
| Malignant Lymphoma: Histiocytic, Lymphocytic, Mixed, |
| NOS, or Undifferentiated Cell Type |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 3/50 (6%) 3/50 (6%) 4/50 (8%) | 1/50 (2%) 2/50 (4%) 2/50 (4%) |
|ADJUSTED (b) | 12.8% 16.5% 13.7% | 3.0% 5.9% 4.8% |
|TERMINAL (d) | 1/12 (8%) 0/11 (0%) 0/8 (0%) | 0/24 (0%) 0/30 (0%) 0/25 (0%) |
|FIRST INCIDENCE (DAYS) | 449 635 580 | 690 674 281 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.282 P=0.591 P=0.408 | P=0.379 P=0.512 P=0.494 |
|INCIDENTAL TUMOR | P=0.482 P=0.656 P=0.604 | P=0.414 P=0.233 P=0.581 |
|LOGISTIC REGRESSION | P=0.409 P=0.659 P=0.521 | P=0.425 P=0.499 P=0.576 |
|COCHRAN-ARMITAGE | P=0.421 | P=0.390 |
|FISHER EXACT | P=0.661N P=0.500 | P=0.500 P=0.500 |
|=================================================================================================================================|
DATE: 09/10/94 EXPERIMENT: 05080 TEST: 01 PAGE 17
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN RATS(OSBORNE MENDEL) -- ALLYL GLYCIDYL ETHER
TERMINAL SACRIFICE AT 106 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 5 PPM 10 PPM | CONTROL 5 PPM 10 PPM |
| | MALE MALE MALE | FEMALE FEMALE FEMALE |
|=================================================================================================================================|
| |
|All Organs |
| Benign Tumors |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 25/50 (50%) 31/50 (62%) 32/50 (64%) | 40/50 (80%) 44/50 (88%) 37/50 (74%) |
|ADJUSTED (b) | 88.2% 100.0% 93.6% | 90.8% 95.6% 92.3% |
|TERMINAL (d) | 9/12 (75%) 11/11 (100%) 6/8 (75%) | 20/24 (83%) 28/30 (93%) 22/25 (88%) |
|FIRST INCIDENCE (DAYS) | 327 500 303 | 474 318 332 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.004 ** P=0.071 P=0.007 ** | P=0.333N P=0.451N P=0.364N |
|INCIDENTAL TUMOR | P=0.016 * P=0.049 * P=0.039 * | P=0.429N P=0.191 P=0.593N |
|LOGISTIC REGRESSION | P=0.010 ** P=0.054 P=0.022 * | P=0.465N P=0.146 P=0.516N |
|COCHRAN-ARMITAGE | P=0.093 | P=0.263N |
|FISHER EXACT | P=0.157 P=0.113 | P=0.207 P=0.318N |
|=================================================================================================================================|
| |
|All Organs |
| Malignant Tumors |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 18/50 (36%) 12/50 (24%) 15/50 (30%) | 12/50 (24%) 19/50 (38%) 17/50 (34%) |
|ADJUSTED (b) | 79.6% 43.2% 64.3% | 34.2% 45.3% 42.0% |
|TERMINAL (d) | 8/12 (67%) 1/11 (9%) 3/8 (38%) | 4/24 (17%) 8/30 (27%) 4/25 (16%) |
|FIRST INCIDENCE (DAYS) | 449 444 300 | 269 318 220 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.372 P=0.293N P=0.358 | P=0.196 P=0.210 P=0.223 |
|INCIDENTAL TUMOR | P=0.423N P=0.165N P=0.502N | P=0.178 P=0.042 * P=0.258 |
|LOGISTIC REGRESSION | P=0.406N P=0.171N P=0.501N | P=0.194 P=0.100 P=0.222 |
|COCHRAN-ARMITAGE | P=0.293N | P=0.167 |
|FISHER EXACT | P=0.138N P=0.335N | P=0.097 P=0.189 |
|=================================================================================================================================|
DATE: 09/10/94 EXPERIMENT: 05080 TEST: 01 PAGE 18
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN RATS(OSBORNE MENDEL) -- ALLYL GLYCIDYL ETHER
TERMINAL SACRIFICE AT 106 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 5 PPM 10 PPM | CONTROL 5 PPM 10 PPM |
| | MALE MALE MALE | FEMALE FEMALE FEMALE |
|=================================================================================================================================|
| |
|All Organs |
| Malignant and Benign Tumors |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 30/50 (60%) 37/50 (74%) 39/50 (78%) | 43/50 (86%) 47/50 (94%) 44/50 (88%) |
|ADJUSTED (b) | 96.5% 100.0% 97.3% | 93.4% 97.9% 95.5% |
|TERMINAL (d) | 11/12 (92%) 11/11 (100%) 7/8 (88%) | 21/24 (88%) 29/30 (97%) 23/25 (92%) |
|FIRST INCIDENCE (DAYS) | 327 444 300 | 269 318 220 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.002 ** P=0.058 P=0.003 ** | P=0.473 P=0.442N P=0.507 |
|INCIDENTAL TUMOR | P=0.004 ** P=0.034 * P=0.009 ** | P=0.315 P=0.155 P=0.398 |
|LOGISTIC REGRESSION | P=0.003 ** P=0.028 * P=0.006 ** | P=0.308 P=0.129 P=0.397 |
|COCHRAN-ARMITAGE | P=0.031 * | P=0.436 |
|FISHER EXACT | P=0.101 P=0.041 * | P=0.159 P=0.500 |
|=================================================================================================================================|
(a) Number of tumor-bearing animals / number of animals examined at site.
(b) Kaplan-Meier estimated lifetime tumor incidence after adjustment for
intercurrent mortality.
(d) Observed incidence at terminal kill.
(f) Beneath the control incidence are the P-values associated with the trend
test. Beneath the dosed group incidence are the P-values corresponding to
pairwise comparisons between the controls and that dosed group. The life
table analysis regards tumors in animals dying prior to terminal kill as
being (directly or indirectly) the cause of death. The incidental tumor
test regards these lesions as non-fatal. Logistic regression is an alternative
method for analyzing the incidence of non-fatal tumors. The Cochran-Armitage
and Fisher's exact tests compare directly the overall incidence rates.
For all tests, a negative trend is indicated by "N".
(e) Value of Statistic cannot be computed.
(I) Interim sacrifice
(T) Terminal sacrifice
# Tumor rates based on number of animals necropsied.
* To the right of any statistical result, indicates significance at (P<=0.05).
** To the right of any statistical result, indicates significance at (P<=0.01).
--multipart-boundary
Content-type: text/plain
Range: bytes 125179-125179/125179
--multipart-boundary--